full comment requir non-u analyst conflict disclosur
pleas click link
ms franchis continu hold tight despit competit push pull
confirm zambian revenu author letter assess unrealist
increas pt mirvetuximab combo opportun ahead key catalyst
live think day ceo ai keynot
fourth quarter preview survey result
termin servic agreement materi reduc cost
increas pt celg neurosci collabor ahead key catalyst
adcetri approv stage iii/iv hl tailwind toward potenti
analyst meet highlight cyber train data analyt isr capabl
sens thought price action/
strong durabl
 of daili summari
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site use ipad app research
user group analyst day take
pay integr prize
price prior day market close estimate unless otherwis note
valu usd unless otherwis note
increas pt mirvetuximab combo opportun ahead key catalyst
upcom mirvetuximab keytruda dose-escal data sgo could provid
initi indic combo synergist activ synergist orr
could lead upsid given potenti combo broadli use
earlier line recurr platinum-resist ovarian cancer vs downsid
 share trade back level pre-rec run efficaci signal
anticip efficaci signal could suggest potenti broader
mirvetuximab modeling/penetr contrast see
recent appreci indic investor anticip efficaci
signal expect share could trade back level prior recent run
downsid howev note could present buy opportun
ahead updat later year dose expans data much larger
popul potenti valid immuno-oncolog combin ovarian
cancer think downsid safeti signal prevent
combo move forward unlik given lack signal
mirvetuximab combo avastin chemo last seen
increas pt celg neurosci collabor ahead key catalyst
see prta/celg neurosci collabor ad non-dilut fund
key partner earli stage pipelin see extern interest ad valid
discoveri engin provid addit downsid protect ahead
pronto read-out mid-year updat model reflect
celg cash equiti invest increas pt pipelin
remain upsid pt
today market close announc pre-clin neurosci
collabor celg develop therapeut target includ
tau third undisclos target recal clinic pre-
clinic work neurosci focus misfold protein highlight
 day see takeaway today management reiter
uniqu discoveri capabl identifi novel therapeut epitop
misfold protein implic diseas tau well
expertis gener antibodi block bind misfold
protein cell addit inhibit pathogen cell-to-cel interact
critic diseas onset progress view today announc
collabor celg extern valid intern expertis
compani potenti engin see collabor
associ cash infus limit downsid ahead key readout
pronto lead asset howev anticip outcom
upcom trial like view read-through across
 platform posit neg scenario albeit
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
limit downsid given today implic cash infus extern pipelin
fourth quarter preview survey result
believ red hat remain well posit adopt hybrid-cloud
servic contain momentum acceler base channel convers
 survey result feel demand environ remain strong despit
difficult well document bill compar maintain op bump target
increas estim addit confid strateg posit
need know red hat announc result
check point strong demand core rhel well addit momentum
emerg product notabl openshift addit use-cas
openstack believ compani remain well posit benefit
long-term trend includ hybrid-cloud support contain
aid recent acquisit coreo addit cross-cloud kubernet
support increas target higher estim add confid
quarterli set-up follow solid result stock initi post-
print investor sentiment remain posit share sinc
print advertis face difficult comp year
consensu look growth roll bill
proxi grow remind y/i compar benefit
bp bill shift well deal
deceler look like qtr long-term trend remain posit us
also pay attent vs consensu expect upsid vs
consensu revenu expect q/q vs three-year averag
q/q look ahead guidanc consensu billings/revenue/
ep expect billings/revenu growth
om expans bp though think margin could flattish
y/i due coreo
adcetri approv stage iii/iv hl tailwind toward potenti
adcetri receiv label stage iii/iv hl line expect though
potenti restrict vs expect line prioriti review
advanc hl could enabl use stage iib patient focu
commerci execut updat us financi guidanc guidelin inclus
clinic mileston potenti readout trial
today announc adcetri receiv fda approv front-lin
hodgkin lymphoma hl label stage iii/iv patient line
expect model though potenti restrict vs
investor hope broader label advanc hodgkin lymphoma notabl
approv come ahead may pdufa unsurpris
given view high unmet need previous approv target
therapi adcetri breakthrough prioriti review design
continu like adcetri risk/reward profil stage iii/iv patient anticip
use prophylact growth factor g-csf us improv upon
acdetri real world safeti vs label slightli
valu usd unless otherwis note
valu usd unless otherwis note
narrow advanc hl see label inclus popul
win quell concern label could limit hl patient
stage iv higher risk ip score diseas physician commentari
balanc though overal posit toward supplant current soc
avbd adcetri see investor event takeaway model
forecast potenti adcetri surpass mark us sale broad
penetr stage iii/iv patient reach peak sale inclus
analyst meet highlight cyber train data analyt isr capabl
keyw highlight key technolog cyber train data analyt airborn
isr hanov md analyst meet march keyw expos faster-
grow nich within defens intellig market like setup
acceler revenu growth budget visibl improv expect still low
reset reiter outperform rate
keyw host investor meet near headquart hanov md
includ technolog product demonstr present senior
leader product manag new long-term growth target
ms franchis continu hold tight despit competit push
believ ms franchis perform solidli rbc/con fy
estimate yoy incl ocrevu rel stabl treatment dynam
especi light recent competit setback longer term though
continu believ could import brand gener competit
pressur share price end note two novel treatment
recent emerg data stem cell transplant btk inhibit could
worth watch highlight evolv landscap given complex
potenti side effect sct unlik major immedi competit threat
though outstand efficaci albeit small studi could make option
refractori pt otherwis tysabri ocrevu
impress interim efficaci shown hsct rrm studi result
preliminari approach worth watch
btk inhibit make renew earli wave ms merck kga optimist
evobrutinib ph iib poc
continu view valuat fairli balanc near term stabil
ms franchis strong neurosci platform risk
accompani depend aducanumab growth need addit
confirm zambian revenu author letter assess unrealist
first quantum confirm report press state possess
letter zambian revenu author note assess import
duti penalti interest consum spare part billion
zambian kwacha first quantum unequivoc refut assess
view uncertainti around potenti tax liabil neg although
sell stock appear react
declin market valu
press articl first quantum refer publish bloomberg went
quot tax author say announc preliminari
assess billion kwacha issu promin mine compani
misclassifi consum spare part import last five year
said item declar mine machineri attract custom
duti zero percent fact
base compani report model estim cumul oper
cost past six year zambia estim make
consum mainten part would expect
amount subject custom duti sourc zambia addit
view consum spare part integr on-going mine oper
henc consid mine machineri find propos tax
assess billion kwacha unrealist await detail
assess
live think day ceo ai keynot
need opportun attend morn
keynot ceo ginni rometti svp cognit solut
watson blockchain custom includ senior leader verizon
among other key takeaway day event today
market data cad financi data usd dividend paid
valu usd unless otherwis note
termin servic agreement materi reduc cost
take-away view termin spin-off relat servic
agreement favor given quorum like captur least
in-sourc servic current provid former parent save
repres approxim boost annual ebitda
valu usd unless otherwis note
valu usd unless otherwis note
surpris announc founder/ceo dr randi schatzman
step immedi navig key entrant novel class
incept ph iii leav aldr well-posit well-capit
ip issu see potenti new leadership regulatory/
commerci experi help de-risk eptinezumab file launch
process perhap fresh perspect might also help bridg gap
see epti oppti aldr current market cap
even announc current ceo dr randi schatzman
step immedi board member paul cleveland step
interim ceo
see increment addit chang opportun build valu
capit strong foundat outgo ceo randi schatzman
interim ceo plan conduct full deep dive busi focu
commerci readi bla file believ rapid establish
busi success plan import keep epti bla file
highlight oneplac analyst day compani effort
work collabor broker channel creat new access
monet opportun employ market like strategi await
proof point sale execut
invest broker channel compani retir benefitstor
mean headwind revenu also give broker place
ecosystem support strateg chang
valu usd unless otherwis note
valu usd unless otherwis note
data differenti use new benefitplac platform drive data
standard like help drive intern effici well serv
induc broker
gtm updat sale partner effort sound posit vertic effort
appear success sap partnership advanc
user group analyst day take
see potenti new product monet consum connect loan
offic connect data connect higher effici shorter time close
loan volum market share enterpris segment think volum
headwind moder next year guidanc embed
conservat current volum outlook reiter outperform
manag laid target revenu adj ebitda margin
margin
see potenti lever new product introduct includ
consum connect loan offic connect data connect also see
monet opportun effici higher network servic attach
higher loan volum share
continu view guidanc achievable/ beatabl
current volum assumpt see compani competit posit
reiter outperform pt
think long thesi
need think attract valu name
investor look despit avgo hostil bid fall apart
think ep target optimist see reason
scenario wherebi could achiev ep vs current
street model even temper valuat would peg
stock rang yield furthermor see
multipl attract catalyst next tailwind start
kick tailwind includ nxpi approv mofcom could add
resolut end like could add ep potenti
pick back baseband alloc post resolut net/net
understand histor execut choppi think high
probabl oem disput may settl sooner clear
isnt go anywher furthermor get disciplin consist
execut stock see sustain multipl expans
valu usd unless otherwis note
valu usd unless otherwis note
pay integr prize
announc stock/cash bid mule close today
sap/cnqr orcl/n high qualiti uniqu softwar asset come cheap
mule largest compani histori believ highest
multipl ever signific public saa asset see transact dilut
without synergi assumpt like strateg rational
posit deal less enthus price tag mule
built uniqu sticki mission-crit next-gener middlewar solut
connect legaci system cloud app devic
consensu ev/sal bid mule rank expens
softwar acquisit seen recent histori also stand
largest acquisit histori
origin bp ngom expans guid ngom
maintained/slightli improv think bp y/i better top line trade
think deal margin dilut ep basi
synergi assumpt see exhibit detail
post larg in-lin financi result introduc guidanc line
earlier estim manag announc sale leaseback transact
further compani path toward revenu diversif
believ windstream legal overhang consequ impact cost capit
visibl remain challeng pt unchang
report result met expect consolid revenu
vs rbc/consensu adjust ebitda affo/
share consensu per share manag announc
fiber sale leaseback transact take compani step
closer goal revenu diversif believ windstream legal
overhang consequ impact cost capit visibl nonetheless
remain challeng maintain pt
valu usd unless otherwis note
sum part analysi suggest signific upsid stock
valu usd unless otherwis note
valu usd unless otherwis note
need know analyz valuat sum-of-th part basi
separ valu hdd nand asset hdd portion appli stx
valuat ev/ebitda give wdc hdd busi valu
nand asset look three option valu sale
price toshiba memori assum debt attribut
nand use mu ev/ebitda multipl
appli sndk pre-acquisit averag multipl
conserv case appli toshiba valuat get total valu
premium vs current price high-end appli sandisk
multipl could upsid much valu
share think sndk valuat somewhat optimist given uniqu
leadership planar nand howev sotp differ scenario suggest
under-valued median scenario net/net maintain
outperform rate price target think sizabl potenti ep upsid
room multipl expans remain
drug suppli chain stop make sens thought price
need know comment recent news flow
neg impact drug suppli chain stock view concern
overblown multipl near histor low posit view
esrx share maintain outperform rate believ could take time
see share perform better investor sentiment remain neg
encor trial show elgx ovat strong durabl
elgx held confer call discuss encor clinic result ovat
abdomin stent graft encor analysi includ follow result
valu usd unless otherwis note
valu usd unless otherwis note
valu gbp unless otherwis note
valu usd unless otherwis note
ovat freedom aaa-rel mortal freedom
reintervent type endoleak freedom ruptur
freedom convers freedom device-rel
reintervent believ studi help mitig physician concern
ovat durabl expect elgx releas addit encor sub-studi
ovat clinic trial releas maintain sector perform rate
suggest potenti signific growth howev lynparza appear
current agent choic among survey physician surprisingli survey
respond note lynparza efficaci well toler drove choic
agent clinic treatment decis make continu like
rubraca mainten ahead april pdufa anticip
drug competit safety/efficaci profil enabl captur signific
share remain market move forward look sgo confer
weekend gain qualit parpi color surround decis
make detail quantit survey
inpp result slightli weaker expect
subsidy-fre renew possibl aurora energi research
fortum/ support unip dividend propos
intern of daili
amerisur amer wait age well three could spud
outperform petrofac pfc second indian contract award
result sdx energi sdx test result spud well
morocco gulfsand petroleum delist
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict
capit market may restrict publish research report time time due regulatori restrict and/ intern complianc polici
case latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject
compani capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri
busi secur broker dealer jurisdict full extent permit law neither capit market affili
person accept liabil whatsoev direct consequenti loss aris use report inform contain herein matter
contain document may reproduc copi mean without prior consent capit market
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
